Orbia's Koura Business opens world's first HFA 152a medical propellant production facility
BOSTON, March 31, 2022 /PRNewswire/ -- Koura, a global leader in the development, manufacture, and supply of fluoroproducts and technologies,[2] today opens a new HFA 152a production facility at their Runcorn site in the UK.
- BOSTON, March 31, 2022 /PRNewswire/ -- Koura, a global leader in the development, manufacture, and supply of fluoroproducts and technologies,[2] today opens a new HFA 152a production facility at their Runcorn site in the UK.
- [3]
The opening of this new production facility was conducted by Alessandro Chiesi, CCO at Chiesi and Gregg Smith, President at Koura and marks a key milestone in delivering an environmentally-friendly medical propellant, HFA 152a, which has a low GWP (F-Gas AR4 124). - This new facility will see commercial-scale HFA 152a availability in the market by mid-2022, allowing pharmaceutical companies to meet 2025/2026 commercial product timeframes.
- Gregg Smith, Koura President said: "This is a significant step forward in bringing our sustainable, greener medical propellant HFA 152a to the market.